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Defects in cytoskeleton functions support tumorigenesis fostering an aberrant proliferation
and promoting inappropriate migratory and invasive features. The link between
cytoskeleton and tumor features has been extensively investigated in solid tumors.
However, the emerging genetic and molecular landscape of peripheral T cell
lymphomas (PTCL) has unveiled several alterations targeting structure and function of
the cytoskeleton, highlighting its role in cell shape changes and the aberrant cell division of
malignant T cells. In this review, we summarize the most recent evidence about the role
of cytoskeleton in PTCLs development and progression. We also discuss how aberrant
signaling pathways, like JAK/STAT3, NPM-ALK, RhoGTPase, and Aurora Kinase, can
contribute to lymphomagenesis by modifying the structure and the signaling properties
of cytoskeleton.
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Cytoskeleton is a highly versatile structure and organized by protein filaments (actin filaments,
microtubules and intermediate filaments), which are assembled into dynamic polymers. This
structure is deputed to many crucial functions including the organization of intracellular
compartments, definition of cell polarity, generation of movement, elaboration and transduction
of environmental stimuli (1). During cell cycle, cytoskeleton fibers orchestrate cell division at
different levels including chromosomal segregation and cyto-dieresis. As well, during
morphogenesis and cancer metastasis, cytoskeleton provides the pushing and contractile forces
required for cell migration. Besides its structural role, cytoskeleton functions as integrating hub for
signal transduction. Through the membrane proteins to which it is connected, cytoskeleton collects
inputs from the outside, coordinates their transduction inside the cells and participates to the
elaboration of cellular responses (2).
Finally, constituting the internal scaffold of the cell, cytoskeleton ensures resistance to
mechanical stresses providing functional advances to cancer cells during the metastatic seeding
(1). For these and many other reasons, cytoskeleton is regarded as one of the most crucial aspects of
cancer biology and a highly promising therapeutic target.April 2021 | Volume 11 | Article 6436201
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context of solid cancer, in which overcoming the rigid tissue
organization and reprogramming cell-cell interactions in response
to the uncontrolled cell proliferation largely rely on the internal
cellular architecture (1). However, increasing amount of evidence
underlines the centrality of cytoskeleton also in the hematological
malignancies including T cell lymphomas.
Peripheral T Cell Lymphomas (PTCLs) are an aggressive and
heterogeneous group of nodal, extranodal, cutaneous and leukemic
neoplasms arising from post-thymic maturation of T-cells (3).
PTCL represents 10%–15% of non-Hodgkin’s lymphomas and are
often associated with poor outcome (4). PTCLs are associated with
morphological changes and abnormal cytological organization
pointing to structural alterations (5, 6). Several insights into the
genetic and molecular features of these tumors have been recently
provided by several genome-wide profiling studies. Many genetic
alterations found in PTCLs converge on signaling pathways that
directly or indirectly impact on cytoskeleton organization and
function, even if the complete implication of these alterations has
still to be fully elucidated (7). In this review, we aim to revise the
current knowledge about the role and relevance of cytoskeleton in
PTCLs and to discuss how aberrant signaling including the JAK/
STAT3, NPM-ALK, Rho-GTPase, and Aurora Kinase pathways
contribute to modify structure and function of cytoskeleton in
malignant T cells. Finally, we will discuss the possibility of targeting
cytoskeleton as a potential therapeutic strategy in PTCLs.CYTOSKELETON IS INVOLVED IN THE
REGULATION OF CRUCIAL CELLULAR
PROCESSES OF PTCL BIOLOGY
PTCLs are highly heterogeneous entities which encompass a
wide range of pathological states. In 2017 the World Health
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forms of mature post-thymic T cell-non-Hodgkin lymphomas
among which PTCL–not otherwise specified (PTCL-NOS),
angioimmunoblastic T-cell lymphoma (AITL), anaplastic large
cell lymphoma (ALCLs) and extranodal natural killer cell/T cell
lymphomas (ENKTCL) represent the most frequent variants (3)
(Figure 1 and Table 1).
The transforming events in PTCLs lead to the acquisition of
unique abilities to response to external stimuli. PTCLs not only
show defects in T cell receptor (TCR) activation that drives the
generation of T cells with unique and specialized functions (8)
(9) but also show a deregulation of complex transcriptional
programs that foster cellular transformation leading to the
generation of neoplastic cells with new features (10–12). Of
note, PTCLs are characterized by aberrant cell division,
apoptosis, cell adhesion, matrix remodeling, cell migration, and
cytokines secretion (7) all processes that reflect profound
changes in T-lymphocytes cytoskeleton organization/dynamics
leading to changes in T lymphocytes polarity.
In T-lymphocytes, the reorganization of cytoskeleton is a
rapid, dynamic and a tightly regulated process which involves
actin filaments and microtubules. Each of these components
regulate unique but integrated aspects of T cells.
The assembly and disassembly of filamentous (F)-actin is
crucial to generate movement structures like filipodia,
lamellipodia, stress fibers, and uropodia (2). The formation of
these elements is orchestrated by a large number of Actin Binding
Proteins (ABPs). These proteins span several functions including
the regulation of the availability of actin monomers for
polymerization, promoting de novo filaments formation
(nucleation), priming actin filaments elongation, capping barbed
or pointed ends to terminate elongation, and bridging physical
connection among actin filaments (13). Mice models and humans
lacking ABPs show profound defects in T-lymphocytes
development and activation (14) highlighting the importance of
these proteins in the homeostasis of T-lymphocytes.
Microtubules are formed by polymers of tubulin and nucleate
from a microtubules-organizing center (MTOC). They regulate
the polarized secretion of effector molecules and contribute to
the maintenance of F-actin-dependent structures (15–17). Also
microtubules are highly plastic and dynamic structures and
orchestrated by microtubule-stabilizing and destabilizing
proteins including microtubules-associated proteins (MAPs),
Lissencephaly 1 (Lis1), stathmin, and tau protein (18–20).
Interesting, Lis1-deficient murine models show a reduction in
the number of both CD4+ and CD8+ lymphocytes in the
periphery and aberrant CD8+ differentiation into long-lived
memory cells suggesting that Lis1 controls homeostasis of T
lymphocytes (18).
A cross-talk between actin and microtubules is required to
ensure a correct T cell receptor (TCR) activation, signaling and
TCR-dependent processes (like the formation of immunological
synapse (IS), of pseudopodia formation/extension which affect
lymphocytes direction of migration, changes in morphology and
the polarized secretion of cytokines and lytic granules) (21).
Disruption of actin fi laments by inhibitors of actin
polymerization impairs T-cell activation and drasticallyApril 2021 | Volume 11 | Article 643620
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of microtubules by microtubules-destabilizing agents enhances
traction stresses, increases Rho-GTPases activity and induces
random and not polarized secretion of cytokines after TCR
activation (15, 16).
Immediately after TCR activation, the activation of Src
tyrosine kinases (PTKs) leads to a subsequent phosphorylation
of effector signal molecules such as Linker for Activation of T cell
(LAT) and the leukocyte-specific homolog of cortactin HS1
occurs (24). HS1 independently bind the actin related protein
(Arp)2/3 complex and stabilize F-actin. HS1-deficient T-cells
and mice showed peculiar defects in actin polymerization at the
IS with the generation of unstable and chaotic actin-rich
structures. The inefficiently disassembly of polymerized F-actin
fails to sustain Ca2+ influx and the activation of NF-AT and NF-
kB–dependent activation of IL-2 promoter impacting on T-cell
proliferation negatively (25). Instead, LAT activates the Vav
guanine nucleotide exchange factor (Vav1) and RhoGTPase
signaling pathway leading to the modulation of several ABPsFrontiers in Oncology | www.frontiersin.org 3and resulting in a rapid a massive F-actin polymerization (Figure
2A). Indeed, F-actin polymerization in proximity IS leads to the
formation of lamellipodia, increasing the interactive T cell- APC
surface area and organizing the mature IS (14). Later, actin
filaments undergo spatial reorganization to guarantee
pseudopodia formation/extension which in turn affects
lymphocytes direction of migration (26). In parallel, the
orchestrated rearrangement of actin filaments underlies T
lymphocytes morphology that changes from spherical to
elongated. Finally, actin polymerization promotes the assembly
of signaling microclusters at periphery of IS and drives their
centripetal flow toward the central region where signal
termination takes place (27) (Figure 2B).
TCR-activation also controls the movement of microtubules
and microtubule-associated proteins (28). For instance, tubulin,
the main component of microtubules, undergoes dramatic
changes promoting translocation of MTOC to the IS. This step
is crucial to obtain maturation of IS, to promote microtubules
growth and to guarantee the polarized secretion of cytokines andFIGURE 1 | Classification of the most recurrent T cell lymphoproliferative disorders. World Health Organization (WHO) classification of PTCLs. In light blu aggressive
subtypes and in light pink indolent subtypes. Adapted from Swerdlow S.H. et al. WHO Classification of Haematopoietic and Lymphoid Tissue. Revised 4th edition.
Ed. Lyon:2017. EBV, Epstein Barr virus.TABLE 1 | The most frequent PTCL subtypes: incidence and genetic alterations.
Subtypes Incidence (%) among PTCLs 5-Year OS (%) Recurrent Genetic Alterations
PTCL-NOS 25.9 32 TBX21, GATA3, ITK-SYK, CTLA4-CD28, RHOA, VAV1,
AITL 18.5 32 TET2, DNMT3A, RHOA, IDH2, CD28, FYN, VAV1
ALK+ ALCL 6.6 70 ALK fusion proteins
ALK- ALCL 5.5 50 JAK/STAT3, DUSP22, TP63, IRF4, NCOR2-ROS1, NFKB-ROS1, NFKB2-TYK2
BIA-ALCL not available 89-91 STAT3, SOCS3, TP63, DNMT3A
ENKTCL 10 <50 JAK3, STAT3, STAT5B, MLL2, ARID1A, EP300, ASXL1, EBV infection
Intestinal TCL 5 20 STAT5B, TET2, SETD2PTCL, peripheral T cell lymphoma; PTCL-NOS, PTCL-not otherwise specified; AITL, angioimmunoblastic T cell lymphoma; ALK+ALCL, anaplastic lymphoma kinase positive anaplastic
large cell lymphoma; ALK-ALCL, anaplastic lymphoma kinase negative ALCL; BIA-ALCL, breast implanted associated ALCL; ENKTCL, extranodal natural killer cell/T cell lymphoma.April 2021 | Volume 11 | Article 643620
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positive feedback–loop on Rho-GTPase activity to ensure a stable
and polarized direction of migration (30).
F-actin and microtubules undergo rearrangement during
mitosis controlling segregation of chromosomes, positioning of
the contractile ring and completion of cell cleavage to guarantee
full cytokinesis (31).
Different classes of proteins (i.e. microtubules motor proteins,
transcriptional factors, GTPases, kinases and component of
telophase disk) and strong interplay between actin and myosin
are required for a successful cell proliferation and cell
division (31).THE ROLE OF Rho-GTPase IN T CELLS
AND PTCLs
Rho-GTPases are a family of 23 small G proteins that belong to
the Ras superfamily (32). They act as molecular switches which
control a wide variety of signal transduction pathways playing aFrontiers in Oncology | www.frontiersin.org 4pivotal role in the regulation of the actin cytoskeleton and
influencing many aspects of cell biology including adhesion
properties, polarity, membrane transportation, motility and
invasiveness (33). Mechanistically, these proteins switches from
a guanosine diphosphate (GDP)-binding functionally inactive
state to a guanosine triphosphate (GTP)-binding active state (34)
changing their intracellular localization (35).
This thinly regulated balance is orchestrated by guanine
nucleotide exchange factors (GEFs), GTPase activating proteins
and guanine nucleotide dissociation inhibitor (GDIs) (36) that
ensure a correct activation under specific stimuli. RhoA, Rac1,
and Cdc42 are the three typical and most studied members of
Rho-GTPAses family.
The role of RhoA during T cell development has been
extensively investigated in vitro and in vivo highlighting its
fundamental contribution in pre and post-thymic selection of
CD4+ and CD8+ lymphocytes, in chemokine-induced T-
lymphocytes polarization and migration (37) as well as in TCR-
dependent-activation process and spreading after TCR-activation
(38). Upon its activation, RhoA activates several downstream
effectors such as Rho-associated coiled-coil-containing proteinA B
FIGURE 2 | Global regulation of actin cytoskeleton dynamics in T-lymphocytes. (A) The engagement of TCRs with agonist peptide presented by major
histocompatibility complex (MHC) molecules yields actin polymerization and microtubules organization through the activation of LAT, PTKs, and Vav1 and
RhoGTPase signaling pathways. These cascades converge on the modulation of actin binding proteins (ABPs) like HS1, Arp2/3 complex, WASP, WAVE2, and ERMs
family. (B) Representation of actin and microtubules distribution in resting and in Antigen Presenting Cell (APC) interacting T-lymphocyte.April 2021 | Volume 11 | Article 643620
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related formin 1 (mDia1) to modify cytoskeleton flexibility
inducing the formation of stress fibers and focal adhesion,
promoting both depolymerization and polymerization of F-
actin and facilitating cell separation during cytokinesis
increasing acto-myosin contractile ring tension (39).
In addition, RhoA regulates the transcription of serum
response factor (SRF) and myocardin-related transcription
factor (MRTFA) (40, 41), two transcriptional factors that
control the expression of cytoskeleton-related genes and that
induce changes in cellular globular actin (G-actin) concentration,
thereby coupling cytoskeletal gene expression to cytoskeletal
dynamics (Figure 3).
Being a key signal transducer, it is not surprising that RhoA
deregulation has a role in lymphomagenesis. Indeed, the recent
implementation of deep sequencing strategies revealed recurrent
mutations of RhoA in PTCLs, suggesting a driver role for RhoA
in the development of these lymphomas. The most frequent
mutation is G17V, which has been detected in 50% to 70% of
AITL (8, 42), 18% of PTCL-NOS (43), 7% of SS, and 2% of ATLLFrontiers in Oncology | www.frontiersin.org 5(44). G17V RhoA mutation has been studied extensively in the
AITL, where generally arises in a permissive genetic background
in which loss of function of Tet2 has occurred as first hit of
lymphomagenesis suggesting a cooperative role of these
alterations in the pathogenesis of AITL (45). Apparently this
mutation confers suppressive functions to RhoA breaking many
paradigms on the role of this protein in tumors. Mechanistically,
glycine at residue 17 is critical for GTP binding and locks RhoA
in its inactive conformation (43). Its substitution with a valine
residue confers the ability to act as dominant negative preventing
the activation of wild type RhoA and its effectors proteins (45)
and probably by altering the activity of the GEFs resulting in a
reduction of SRF transcription and in the number of F-actin
stress fibers (43).
Of note, G17V RhoA mutant acquires the ability to
significantly increase and to enhance the Inducible T Cell
Costimulator (ICOS) signaling leading to the differentiation of
CD4+ T cells towards the follicular helper T lineage (45, 46),
suggesting that G17 RhoA profoundly modifies the transcription
program of these neoplastic cells leading to the establishment ofFIGURE 3 | Overview of Rho-GTPase signaling in T-cells. Rho GTPases regulate several processes, including cytoskeletal rearrangement, proliferation and cellular
division. The best-characterized Rho GTPase proteins, RhoA, Cdc42 and Rac1 (light green), and some of their main effector proteins are shown (purple). The
Activation or inactivation of cytoskeletal effectors leads to responses such as actomyosin contraction, filamentous (F)-actin disassembly or F-actin polymerization and
microtubules stabilization. RhoA induces the activation of Rho-associated coiled-coil-containing protein kinases (ROCKI and ROCKII) leading to actomyosin-
assembly. Targeting Citron kinase at the cleavage furrow during the cytokinesis, RhoA also increases the acto-myosin contractile ring tension and facilitates cell
separation. Moreover, RhoA induces actin polymerization through the activation of the novo actin polymerizing agent formin mammalian diaphanous (mDIa1). The
binding of Cdc42 to N-WASP or WASP (Neuronal-/Wiskott-Aldrich syndrome protein) and Rac1 to WAVE2 (Wiskott-Aldrich syndrome protein family member 2)
initiates the assembly of protein machineries that are required for actin polymerization and involved the activation of actin binding proteins (Arp2/3 complex) to
stimulate actin polymerization by creating a new nucleation core. Cdc42 also phosphorylates and activates the effector proteins p21-activated kinases (PAKs) to
mediate effects on microtubules and F-actin. Cdc42 and Rac1 are further interconnect by the exchange factor Tiam-1 that, acting mainly upstream of Rac1, is
involved in the regulation of Rac1-mediated signaling pathways.April 2021 | Volume 11 | Article 643620
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mutation confers a tumor suppressor function to RhoA in AITL,
additional mutations in this gene have been reported in other
PTCLs subtypes like Adult T-cell leukemia/lymphoma (ATLL)
(44). The effect induced by either gain or loss of functions RhoA
mutations is heterogeneous and context—specific. In fact,
Nagata et al. reported that in ATLL, HTLV-1 infection
predispose normal T cells to acquire either gain or loss of
function mutations in RhoA that in turn generate highly
different behavior in which T-reg and T-memory phenotypes
co-exist (44). A more comprehensive and detai led
characterization of RhoA functions should help to better
understand its oncogenic role in PTCLs.
Rho-GTPases exert-actin/microtubules dependent and
independent activities being also able to control transcription
changes. Their role in driving the entry and the progression of
the cell cycle is strictly linked to dynamic changes and
reorganizations of the actin cytoskeleton (47).
After TCR-activation, Rac1 promotes the assembly of protein
machineries that are required for actin polymerization to
stimulate this process by creating a new nucleation core. In
addition, through the activation of p21-activated kinases (PAK)
members, it also regulates microtubules stabilization in order to
balance the force of the mitotic spindle (48). In parallel, Rac1 also
promotes the activation of transcriptional factors involved in
clonal expansion of T cells such as STATs, c-Jun, activator
protein 1 (AP1), Nuclear factor kappa-light-chain-gene
enhancer of activated B cells (NF-kB) and ETS-like
transcriptional factor (ELK) promoting IL-2 and the a chain of
the IL-2 receptor transcription (49, 50). By the regulation of these
processes, Rac1 ensures a multilevel and precise control of
cell proliferation.
In PTCLs, Rac1 plays a prominent role in ALK+ALCL
subtype where it is often hyperactivated and involved in the
oncogenic program triggered by the NPM-ALK signaling (51,
52) (this aspect will be discussed in details in the next paragraph).
Rac1 results also overexpressed in mantle cell lymphoma where
correlates with poor patient’s overall survival. Instead, in p53-
deficient lymphoma cells, its overexpression reduces the
proliferation (53). As p53 aberrant function is associated with
poor prognosis and poor responsiveness to conventional
treatment options, Rac1 might be a promising drug-
therapeutic target for these patients.
Regulation of RhoGTPases is extremely complex. GEFs are
proteins implicated in the activation of GTPases by stimulating
the release of guanosine diphosphate (GDP) to allow the binding
of guanosine triphosphate (GTP). Due to their role as activators,
GEFs are considered pro-oncogenic proteins (54).
In PTCLs, GEFs like T Cell Lymphoma Invasion And
Metastasis 1 (Tiam1) and Vav1 are emerging as drivers of T
cell transformation (55).
Tiam-1 is a highly conserved protein (56) which activates and
connects Rac1, Cdc42 and in a less extent RhoA promoting actin
nucleation and branching (57), chemokine-induced polarization
and chemotaxis of T cells (58) (59). More recently, Tiam-1/Rac1
complex has been found to support Th17 differentiationFrontiers in Oncology | www.frontiersin.org 6program by the direct interaction and recruitment of
transcriptional factor RORgt on Il17 promoter (60).
Despite the fact that in PTCLs we still lack of information
about its upstream regulators, Tiam-1 has been found
overexpressed during lymphoma invasion and metastasis (55)
where promotes infiltration of T lymphoma cells into fibroblast
monolayers (55). Instead, in ATLL, the activation of Tiam-1/
Rac1 axis promotes the formation of lamellipodia sustaining the
adhesion to stromal cells and tumor infiltration (61).
However, in other contexts, like as chronic lymphoblastic
leukemia (CLL) and colorectal cancer, the overexpression of
Tiam-1/Rac-1 axis leads to transcriptional activation of c-Myc
and cyclin D thereby promoting cell cycle entrance and cancer
cells proliferation (62, 63). Due to the relevance of these
observations and, being the overexpression of Myc associated
to poor clinical outcome in PTCLs (64), the relationship between
Tiam-1/Rac1 and Myc will be an interesting point to address in
the regulation of PTCLs proliferation.
Vav1 is a GEF essential for the accumulation of F-actin at the
immunological synapses (65, 66), for cytokine production and T
cell proliferation (67).
Vav1-dependent Rac activation seems to be involved in the
inactivation of ERM proteins (Ezrin, Raxin, and Moesin). These
are ABP proteins acting as bridge between actin filaments and
plasma membrane to stabilize cortical actin (68) and in
particular, Ezrin inactivation decreases cellular rigidity and
more efficient APC recognition (69). Ezrin depleted T
lymphocytes do not show alteration in TCR signaling or IS
organization but show a partial defects in IL2 production (70)
and in homing to secondary lymphoid organs (71). Interesting,
Ezrin has been evaluated in a cohort of 193 nodal PTCLs
highlighting how its expression is associated with T cell
receptor beta (TCR-beta) and TCR co-receptor CD3. Of note,
the high expression of Ezrin and TCR-beta identified a group of
patients with better overall survival and these proteins have been
identified as independent prognostic factors (72). Due the
relevance of these observations, a correlation between Ezrin
and Vav1 could be an interesting point to address.
Vav1 is aberrantly expressed in many cancers (73). Vav1
deficient patients and Vav1 loss of function lymphomas murine
models of lymphomas show defects in F-actin accumulation, F-
actin reorganization in response to TCR/CD28 co-engagement
(74, 75) and the impairment in both positive and negative
selection of T cells in the thymus (76).
Gain of function mutations and fusions, such as VAV1-
THAP4, VAV1-MYO1F, and VAV1-S100A7 have been found
in adult T cell leukemia (77) and in PTCLs (78) with dismal
overall survival and results in a constitutive active conformation
of Vav1 and a consequent transcriptional increase of
chemokines (78).
As mentioned above, also Vav1-dependent RhoA activation is
fundamental to modulate TCR signaling cascade (75) and Vav1
and RhoA mutations were found to be mutually exclusive in
AITL. Both lead to enhanced TCR signaling (9, 79), suggesting
that this activation is a critical for T-lymphomagenesis as already
described for BCR in B-lymphomagenesis (80).April 2021 | Volume 11 | Article 643620
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REGULATION OF ALK+ ALCL SUBTYPE
Anaplastic lymphoma kinase is a tyrosine kinase receptor (TKR)
belonging to the Insulin Receptor superfamily. Its physiological
role has been limited studied in mammals suggesting its
involvement in neuronal cell differentiation and regeneration
(81). In tumors, ALK gene is often affected by translocation in
which its intracytoplasmic region is fused with different partners
that provide dimerization domains resulting in a constitutive
activation of multiple signaling pathways, like as RAS/Erk,
PLC-g, PI3K, and Jak/signal transducers and activators of
transcription (STAT) which foster cell transformation and
sustain the neoplastic phenotype (82).
In ALCLs, the presence of a translocation which involved
ALK and the locus of nucleophosmin (NPM) is detectable in up
to 80% of ALK+ALCL and leads to the expression of the
oncogenic fusion protein NPM-ALK and consequential
hyperactivation of ALK signaling (83, 84). Beside promoting
cell proliferation and cell survival, NPM-ALK also affects T-cells
shape and architecture in ALCL (85).
NPM-ALK transformed lymphocytes have enhanced motility
and show an irregular polarized-shape (hence the term
“anaplastic”) and an abnormal distribution of F-actin (52, 86).
This morphology is reversed by the specific inhibition of NPM-
ALK proving a direct link between NPM-ALK and T-cell shape
control in these tumors (86). Mechanistically, NPM-ALK
interacts and activates cytoskeleton-regulated proteins, such as
Paxillin, the Actin Nucleation Promoting Factor (WASP), and
the scaffold protein p130Cas (87) (88), and many Rho-GTPases
like Rac1, Cdc42 and RhoA (86).
WASP is one of the critical target of NPM-ALK signaling in
ALCL. It controls actin polymerization during cytoskeletal
rearrangements leading to the formation of lamellipodia,
filopodia, and podosomes (89). WASP has been linked to
Wiskott–Aldrich syndrome, a recessive disease in which the
WASP-homology domain is often mutated causing WASP
destabilization, dissociation from WAS/WASL-interacting
protein family member 1 (WIP) and lymphoma predisposition
(90, 91). T-lymphocytes from these patients as well as WASP or
WIP-deficient T cells in mice show many structural defects
included the impairment of TCR-mediated signaling, reduced
motility, cytokines secretion and defective localization of actin
polymerization (92, 93).
A recent study highlighted the relevance of WASP and WIP
in the biology of ALK+ALCL, reporting that their expression is
consistently low in these lymphomas thereby suggesting a
potential role as oncosuppressors. Indeed, in mouse models,
reduced expression of these proteins accelerates the development
of NPM-ALK-driven anaplastic lymphoma leading to the
generation of cells with a reduced amount of polarized actin
consistent with defects of actin nucleation and assembly
associated to a complete loss of WASP or WIP (94). WASP
and WIP are regulated at the transcriptional level by the STAT3-
C/EBPbeta complex that binds and repress their regulatory
regions (94). The low expression of WASP in ALCL is alsoFrontiers in Oncology | www.frontiersin.org 7guarantee by NPM-ALK directly, which directly phosphorylates
WASP on Tyr102 favoring its dissociation from WIP and
increasing its proteasome-dependent degradation (95)
(Figure 4).NPM-ALK ALSO CONTROLS CELL SHAPE
MODULATING THE ACTIVITY OF RAC1
AND CDC42
In ALK+ALCL, NPM-ALK affects the activation of Rac1 and
Cdc42 and the re-localization of Cdc42 (86, 96) culminating in
the phosphorylation and activation of p21-activated kinases
PAK2 and on morphologically large cells with a polarized
distribution of F-actin (86).
In accordance with their roles, in vitro and in vivo loss of
Cdc42 or Rac1 in NPM-ALK+ behavior results in impairment/
loss of polarization of F-actin filaments assembly and rounded-
shape cells that are unable to disseminate (52, 86). Instead,
enhanced loss of polarization is observed when Rac1 and
Cdc42 are simultaneously deleted suggesting that Rac1 and
Cdc42 cooperate to control cell morphology (52).
Besides Cdc42 and Rac1, NPM-ALK has also been reported to
affect RhoA activity but with an opposite function. Indeed, one
study showed that NPM-ALK interacts with and inhibits RhoA
in a kinase dependent manner (87). This presumably serves to
further regulate cytoskeleton tension and cells shape. As discuss
above, the inhibition of RhoA is a common mechanism in the
biology of PTCLs. Together these data underline how the active
regulation of NPM-ALK on cell shape and cytoskeleton
remodeling is a fundamental part of the oncogenic program
induced by this genetic alteration in T-cells (Figure 4).STAT SIGNALING AND CYTOSKELETON
REGULATION IN PTCLs
The JAK-STAT pathway controls T-lymphocytes homeostasis
(97, 98), activation, differentiation and cytokines signaling (99–
102), all processes that tightly coordinate the activities of
cytoskeleton (103, 104). This pathway is frequently deregulated
in lymphomas through the loss of negative regulators (105), gain
of function of positive regulator (106) or activating mutations in
JAKs, STATs, and/or its upstream regulators (12) leading to the
constitutive activation of this signaling and to profound
alteration of cell identity (7).
The role of STAT3 in invasion and dissemination of solid
tumor and B-lymphomas (107) has been extensively investigated
where canonical and non-canonical function of this transcription
factor in regulating cell migration has been proposed. In these
contexts, STAT3 promotes the transcription of RhoA and RhoH
(107) and also positively regulates the activity of Rac1 by a direct
bind with the GEF bPIX. Moreover, STAT3 binds and probably
sequesters the microtubule-destabilizing protein Stathmin
leading to the stabilization of microtubules and promoting cellApril 2021 | Volume 11 | Article 643620
Fragliasso et al. Cytoskeleton Dynamics in T-lymphomasmigration (108). Up to now, only two studies have explored the
role of STAT3 in PTCLs reporting a classical transcriptional
influence of this factor on cytoskeleton regulation. As mentioned
before, the first study showed that in ALK+ ALCL, constitutively
activated STAT3 binds to C/EBPbeta and represses the
transcription of WASP. This causes profound alterations in
cells shape and morphology associated with abnormal F-actin
distribution (94). In agreement with a transcriptional function of
STAT3 in cytoskeleton regulation in T-cell lymphomas, we
recently reported that in the context of ALK-ALCL, STAT3
controls the expression of a novel long coding RNA (lncRNA)
called BlackMamba. BlackMamba is a chromatin-enriched
lncRNA that controls the expression of several cytoskeleton-
related targets including Ras Homolog Family Member UFrontiers in Oncology | www.frontiersin.org 8(RhoU), RhoA and PAK2 through the transcriptional
regulation of DNA helicase HELLS and its recruitment to
regulatory regions of cytoskeleton genes (Figure 4). We
showed that the loss of BlackMamba or HELLS leads to a
significant inhibition of cell proliferation in ALK-ALCL which
is associated with slow rate of duplication and by the increase of
multinucleated cells (109). Indeed, these cells showed partial
defects in central spindle organization and dramatic defects in
cleavage furrow formation impacting on cytokinesis completion
(110). This phenotype, strictly attributable to HELLS-dependent
regulation of Rho-GTPases, underlines the not always recognized
fact that cytoskeleton is not only required for cell shape and
movement but it is crucial also for cell cycle progression and
proliferation. This function assumes particular relevance inFIGURE 4 | Signaling pathways aberrantly expressed in PTCLs. The aberrant cytoskeleton dynamics and regulation in PTCLs is sustained by several mechanisms.
TCR signaling pathway is often constitutively active in PTCLs leading to an aberrant RhoGTPase signaling cascade and downstream effects. In anaplastic large cell
lymphoma (ALCL), the nucleophosmin (NPM)–anaplastic lymphoma kinase (ALK) fusion hyperactivates Rac1 and Cdc42 leading to the constitutive activation of
downstream effectors (PAK, Tiam1, WAVE and N-WASP), to the increase of F-actin nucleation and polymerization and to an altered microtubules dynamic. ALK
fusion proteins can directly phosphorylate signal transducer and activator of transcription (STAT)3 leading to its localization into the nucleus where, in association with
C/EBPB, repress the expression of WASP. Moreover, NPM-ALK directly inhibits RhoA to regulate cytoskeleton tension and directly phosphorylates WASP to
promote its proteasome-dependent degradation. In ALK-ALCL subtype, activating mutations affecting cytokine receptors, Janus kinases (JAKs) and STAT3 lead to
the constitutive activation of this pathway. The aberrant transcription of lncRNA BlackMamba, of DNA helicase HELLS and a set of genes regulating cytoskeleton
architecture (PAK2, RhoU) leads to a reduction in the amount of F-actin. Mutations in the gene encoding RhoA (G17V) is detected in a subset of angioimmunoblastic
T cell lymphoma (AITL), peripheral T cell lymphoma (PTCL)-NOS and in adult T cell leukemia (ATLL). This mutation contributes to cellular transformation preventing
the activation of wild type RhoA, enhancing the expression of co-stimulatory molecules (ICOS), which in turn contributes to increased PI3K and MAPK signaling and
by reducing the formation of stress fibers. Mutations in the gene encoding Vav1 are found in ATLL, in PTCL-NOS and AITL. These mutations lead to the
hyperactivation of RhoGTPAses and their downstream targets increasing of F-actin nucleation and polymerization. AURKA is overexpressed in ALK+ and ALK−
ALCLs, PTCLs-NOS and cutaneous T-cell lymphomas (CTCLs). Its overexpression leads to hyperactivation of PLK1 and its downstream targets as well as to
hyperactivation of HDAC6 and enhanced microtubules stability.April 2021 | Volume 11 | Article 643620
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documented (6, 111, 112).AURORA KINASE SIGNALING CONTROLS
CELL PROLIFERATION AND CELL
DIVISION
Aurora Kinase A (AURKA) belongs to Aurora kinases family of
serine-threonine kinases (Aurora Kinase A, B and C kinases) that
are highly expressed during mitosis. AURKA has been associated
with multiple phenotypes such as centrosome amplification,
mitotic abnormalities, chromosomal instability, multipolar
spindle and aneuploidy (113, 114).
Many of these features are strikingly observed in AURKA-
overexpressing cells with an initial accumulation of centrosomes
and failure of cytokinesis (115, 116).
AURKA overexpression and different subcellular localization,
is found in 68% of PTCL cases, including ALK+ and ALK−
ALCLs, PTCLs-NOS and cutaneous T-cell lymphomas (CTCLs)
(117). Of note, ALCL is the subtype with the highest frequency of
multinucleation suggesting that, in this subtype more than the
others, cytoskeletal alterations could lead to an abnormal
cytological profile (118). In CTCLs, the overexpression of
AURKA and the hyperactivation of its downstream target
polo-like kinase 1 (PLK1) accelerate mitotic entry of DNA-
damaged cells (119) favoring the accumulation of genomic
aberrations in this lymphoma (120, 121).
Additionally, high risk lymphomas rely on AURKA and
PLK1 to sustain the high rate of proliferation (122). In these
lymphomas, contrary to their canonical role, AURKA/PLK1 axis
promotes the phosphorylation of non-canonical substrates like
c-Myc and Notch which result aberrantly expressed (123)
AURKA also activates its downstream target histone
deacetlyases 6 (HDAC6) to control G0/G1 phase of cell cycle
(124). HDAC6 is the unique member of HDAC family that
participates to acetylation/deacetylation of non-histonic
substrates such as a-tubulin and the ABP Cortactin (125).
Through the deacetylation of a-tubulin, HDAC6 controls the
structure and stability of microtubules. Of note, HDAC6
suppression results in lower microtubule stability and
consequently increases cell stress and death (126). Not only,
HDAC6 deacetylates Cortactin increasing its ability to bind to F-
actin through the activation of Rac1-Arp2/3 complex, thus
promoting F-actin-dependent cell movement (127).
HDAC6 has been linked to several solid tumors (125,
128) and it has also been found aberrantly expressed in
many lymphoproliferative diseases where its overexpression
correlates with an aggressive clinical behavior of PTCLs (129,
130). Indirect observations show that ALK+ALCL cell lines
expressing low level of HDAC6 also express high level of
acetylated a-tubulin (131) suggesting that this pathway could
be involved in aberrant mitotic division of anaplastic cells. Beside
the relevance of HDAC6 in PTCLs biology, this observation
would warrant further investigation in particular in patientsFrontiers in Oncology | www.frontiersin.org 9taking into consideration the raising employment of HDAC
inhibitors to treat hematological malignancies.INDIRECT EFFECTS ON CYTOSKELETON
OF PTCLs APPROVED DRUGS
Targeting pathways converging on cytoskeleton is a strategy
currently investigated in many tumors (132). Indeed, based on
what discussed above, perturbing actin polymerization and/or
microtubule integrity may likely have detrimental effects on both
lymphomagenesis and tumor progression.
Unfortunately, most actin-targeting drugs have not succeeded
in preclinical trials whereas microtubules-targeting agents are
already in use in clinical practice and have proved to be effective
against many types of cancer (132). Among these, paclitaxel,
which controls microtubule polymerization/stabilization and
induces cells mitotic arrest in neoplastic cells, was one of the
first agents to be discovered (133). Paclitaxel is approved by Food
and Drugs Administration (FDA) for the treatment of lung,
ovarian, breast cancer, prostate and Kaposi’s sarcoma. It is also
used off-label to treat lymphoma, and leukemia.
Moreover, considering the centrality of RhoGTPase signaling,
targeting components of this pathway could represent an
effective strategy. However, the development of RhoGTPase
selective inhibitors is still at its infancy and no small molecules
are clinically available (134).
The standard approach to the treatment of PTCLs involves
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
chemotherapy regimen, and autologous stem cell transplant
(135), but the complexity and heterogeneity of PTCLs require
often more personalized approaches to improve outcome and
reduce relapse/refractory events. In spite of advances in the
development of specific inhibitors, none of the FDA approved
drugs for the treatment of PTCL targets the cytoskeleton directly.
However, many of PTCL-approved drugs may have indirect effect
on cytoskeleton components (Figure 5 and Table 2).
Crizotinib, is a specific and selective inhibitor of NPM-ALK
and it has shown a significant activity in a small number of
patients with relapsed ALK+ ALCL. Crizotinib not only
indirectly targets the cytoskeleton inhibiting the activity of
NPM-ALK (136) but also directly affects microtubules
organization through the phosphorylation of RhoGTPase
CdC42 (137).
Ruxolitinib and tofacitinib are small molecules that target the
activation of the JAK/STAT pathway and that are currently
(ruxolitinb) in clinical trials in B-cell NHL and PTCLs
(#NCT02613598). As discussed above, the cytoskeleton
components are among the downstream targets of the JAK/
STAT pathway. Furthermore, in preclinical models, Ruxolitinib
has been shown to inhibit migration of dendritic cells through
the off target inhibition of RhoGTPase ROCK (138) enforcing
the hypothesis that alteration of cytoskeleton function may be
among the cytotoxic effects caused by these drugs in T-
lymphoma cells.April 2021 | Volume 11 | Article 643620
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cycle/division and affects among the others the interaction
between chromosome and cytoskeleton during chromosomal
segregation. Targeting this complex has proved encouraging
results in several tumor settings. Alisertib a selective small
molecule against AURKA have been tested in clinical
trials in lymphomas without reaching impressive results
(#NCT01482962). Currently, new selective inhibitors targeting
the AURKA/PLK1 pathway have been developed, among which
volasertib, a potent PLK1 inhibitor, seems to have encouraging
results. According with the molecular model proposed, volasertib
induce MYC transcriptional repression by impairing the
recruitment of Bromodomain-containing protein 4 BRD4 on
Myc promoter (139). This phenomenon leads to massive
apoptosis in cell lines and in tumor xenograft models of
aggressive T lymphomas (140). Interesting, low concentrations
of volasertib in combination with HDAC inhibitor Belinostat
synergistically induce apoptosis in NHL (141).CONCLUDING REMARKS
The most recent genetic and molecular profiling studies have
unveiled a critical role of cytoskeleton during the transformation
of T cells. Although we still lack of a definitive overall view of
how T cells cytoskeleton change during lymphomagenesis, theFrontiers in Oncology | www.frontiersin.org 10emerging picture suggests that the cytoskeleton transcends the
maintenance of cell morphology and polarity providing a more
complex support to T cells in the response to intrinsic and
environmental clues.
On one side, F-actin and microtubules sustain the aberrant
TCR signaling that is common event in PTCLs. On the other
side, they integrate the complex network of signal transduction
pathways favoring the expansion and survival of neoplastic cell.
In fact, the majority of signaling pathways deregulated in
PTCLs converge on an aberrant regulation of cytoskeleton
components further highlighting how this is a common event
in the development of PTCLs and corroborating the idea that the
cytoskeleton is an appealing structure to target.
For instance, while much attention has focused on the effects
Rho-GTPase and NPM-ALK signaling pathways on cytoskeleton
dynamics, other pathways like as JAK/STAT and AURKA need
to depth studies, especially with the perspective to a continuous
development and improvement of specific inhibitors.
The complexity and heterogeneity of PTCLs mirror the
difficulty to target these neoplasms successfully. The past few
years have witnessed the increase in the development and
approval of new selective inhibitors, but none of these exert
effects on cytoskeleton components directly.
Although important steps forward have been made in
defining the patho-biological mechanisms of PTLCs, still many
shadow areas and unresolved questions remain, leaving a




FIGURE 5 | Signaling pathways linked to cytoskeleton rearrangement and their inhibitors in PTCLs. (A) NPM-ALK kinase regulates cell shape and actin dynamics
through the interaction with RhoA and Paxillin and the activation of Cdc42. (B) The constitutive activation of AURKA leads to phosphorylation and activation of PLK1
causing to an aberrant cell division. (C) Alterations of RhoGTPase result in Rho-GTP active conformation leading to a global alteration of actin homeostasis and
cytoskeleton dysfunction. (D) The aberrant activation of JAK signaling lead to hyperactivation of STAT3 that exerts its action on cytoskeleton regulation through
WASP and lncRNA BlackMamba.April 2021 | Volume 11 | Article 643620
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regulation in PTCLs, could help in the discovery of new
vulnerability of these neoplasms and in the development of
more efficient inhibitors.AUTHOR CONTRIBUTIONS
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Inhibitor Target Lymphomas subtypes Study Phase Identifier





Phase 2: Active, not
recruiting
Phase 2: Active, not
recruiting










Ruxolitinib JAK1, JAK2 Relapsed/refractory Hodgkin lymphoma
Relapsed/refractory Hodgkin lymphoma
Lymphoma, non-Hodgkin
Relapsed or refractory Hodgkin lymphoma
Relapsed or refractory T or NK cell lymphoma








Tofacitinib JAK1, JAK2 NA NA NA
Alisertib AURKA ALCL
AITL
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
hepatosplenic T-cell lymphoma
Mature T-cell and NK-cell
Non-Hodgkin lymphoma
Recurrent adult Hodgkin lymphoma
Recurrent adult immunoblastic lymphoma
Recurrent adult lymphoblastic lymphoma
Recurrent ATLL
Recurrent mantle cell lymphoma
Recurrent mycosis fungoides and sezary syndrome
Recurrent non-Hodgkin Lymphoma
Recurrent primary cutaneous T-cell non-Hodgkin lymphoma
Adult nasal type ENKTCL ALCL
Hepatosplenic T-cell lymphoma
Mature T-cell and NK-cell non-Hodgkin lymphoma


























Recurrent adult diffuse large cell lymphoma
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